EC
EcoR1 Capital Portfolio holdings
AUM
$1.69B
This Quarter Return
-10.99%
1 Year Return
+7.54%
3 Year Return
+113.08%
5 Year Return
+306.58%
10 Year Return
+4,328.75%
AUM
$2.94B
AUM Growth
+$2.94B
(-23%)
Cap. Flow
-$70.7M
Cap. Flow
% of AUM
-2.41%
Top 10 Holdings %
Top 10 Hldgs %
73.2%
Holding
58
New
6
Increased
6
Reduced
4
Closed
8
Top Buys
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$250M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$207M |
| 3 |
Tango Therapeutics
TNGX
|
$52.6M |
| 4 |
Neumora Therapeutics
NMRA
|
$29.2M |
| 5 |
Arvinas
ARVN
|
$28.5M |
Top Sells
| 1 |
Sarepta Therapeutics
SRPT
|
$419M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
$114M |
| 3 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$54.2M |
| 4 |
Revolution Medicines
RVMD
|
$44.9M |
| 5 |
Dyne Therapeutics
DYN
|
$8.99M |
Sector Composition
| 1 | Healthcare | 99.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Zentalis Pharmaceuticals
ZNTL
$123M
| – | – |
-300,000
| Closed | -$8.46M |
|
|
52
Sarepta Therapeutics
SRPT
$1.98B
| – | – |
-3,660,798
| Closed | -$419M |
|
|
KRON
53
DELISTED
Kronos Bio
KRON
| – | – |
-326,780
| Closed | -$562K |
|
54
Johnson & Johnson
JNJ
$429B
| – | – |
0
| – | – |
|
55
Janux Therapeutics
JANX
$1.38B
| – | – |
-452,590
| Closed | -$5.37M |
|
56
4D Molecular Therapeutics
FDMT
$302M
| – | – |
-66,978
| Closed | -$1.21M |
|
|
57
Dyne Therapeutics
DYN
$1.92B
| – | – |
-798,701
| Closed | -$8.99M |
|
|
BPMC
58
DELISTED
Blueprint Medicines
BPMC
| – | – |
-1,798,300
| Closed | -$114M |
|